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This study was a prospective screening study for PPD and anergy
skin test reactivity in 304 H/V-positive individuals. A PPD positivity
rate of 4. 1% and an anergy rate of 50.5% were observed. The Hawaii
H/V population has a relatively low prevalence of latent TB com
pared with the high prevalence of TB in the Hawaii population at
large.
Introduction
Tuberculosis is a major cause of morbidity and mortality in HIV
infected individuals and constitutes an AIDS-defining opportunis
tic infection under CDC’s Revised Classification System for HIV
Infection.1The risk of progression from latent to active disease for
a person co-infected with TB/HIV is estimated to be 7% to 10%
annually as compared to a 10% lifetime risk in HIV-seronegative
individuals.2
Among the opportunistic infections affecting HIV-infected indi
viduals, tuberculosis is unique in that it is usually preventable and
curable if detected early. Diagnosis of latent infection, however.
may be difficult, as a high degree of anergy has been reported in the
HIV-infected population, reducing the sensitivity of the tuberculin
skin test.3’
The CDC in April 1991 made several recommendations for the
diagnosis of latent TB infection in HIV-infected individuals.6Spe
cifically, recommendations called for companion testing with two
delayed-type hypersensitivity (DTH) test antigens in association
with the standard Mantoux method PPD tuberculin (5 TU) testing.
A PPD cut off of 5 mm in this population was recommended as
evidence of tuberculosis infection.
According to the CDC, in 1994 Hawaii had the highest TB case
rate in the nation with 20.9 cases/100,000 individuals.7Little is
known, however, about the rate of PPD reactivity in the HIV
infected population in Hawaii.
The aims of this study were to determine the rate of PPD reactivity
in the HIV-infected community in Hawaii, to correlate the utility of
PPD in this HIV population with a suspected high degree of anergy,
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and to correlate PPD and anergy result with immune status of these
individuals as measured by peripheral blood absolute CD4 and CD8
lymphocyte subset determinations.
Materials and Methods
This study was a three year. prospective, single-center screening
study for PPD and anergy skin test reactivity. HIV-infected persons
age 12 years were recruited through AIDS service organizations
and primary health-care providers for voluntary PPD and anergy
skin testing. Participants were recruited from all major islands in the
state. Demographic data including age, place of birth, ethnicity.
HIV risk factors, history of previous PPD, and history of BCG
vaccination were obtained for each participant. Three hundred
individuals were targeted. Those with a history of sensitivity or
intolerance to screening agents, history of previous positive PPD or
history of tuberculosis were excluded.
The antigens and concentrations used to determine DTH were as
follows: Tuberculin purified protein derivative (PPD) (Connaught
Laboratories, Ltd, Willowdale. Ontario, Canada). 5 tuberculin units
(TU) per 0.1 mL; mumps skin test antigen (MSTA) (Connaught
Laboratories, Ltd. Willowdale, Ontario, Canada), 4 colony-forming
units (CFU) per 0.1 mL; and tetanus toxoid fluid (Wyeth Laborato
ries, Inc, Marietta. Pennsylvania). The tetanus toxoid antigen was
prepared by adding 0.2 ml of fluid tetanus toxoid to 1.8 ml of sterile
albumin saline with phenol (Hollister Stier/Miles, Spokane. Wash
ington), to provide a 1:10 dilution containing 0.1 LFU per 0.1 rnL.
Sterile albumin saline contains 0.9% sodium chloride, 0.03% albu
min (human), and 0.4% phenol in water for injection. The skin tests
were applied to the volar aspect of the right forearm using standard
Mantoux technique. Skin tests were read once between 48 to 72
hours post-skin-test placement by trained personnel. The largest
transverse diameter of palpable induration at each site was mea
sured and recorded. A positive response was defined as 5 mm of
induration in response to PPD and any induration in response to
mumps or tetanus. Anergy was defined as negative response to all
three antigens. Those individuals with less than 5mm of induration
to PPD underwent retesting with all three antigens.
Blood was drawn for T-lymphocyte subset analyses by flow
cytometry within three months of skin testing. Patients with positive
PPD and patients with anergy underwent medical evaluation by
study personnel and chest x-ray examination for evidence of active
tuberculosis. Those with positive PPD were referred for additional
evaluation and treatment. They were offered enrollment into AIDS
Clinical Trials Group 177 TB Prophylaxis study or referred to their
primary physician or the Hawaii Department of Health.
Analysis of data to determine any significant differences or
associations between variables was done using the chi-squared test
of association with continuity correction and Fisher’s exact test.
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Results
A total of 304 individuals were enrolled in the study between
January 1993 and March 1995 (Table 1). Complete results of skin
test reactivity were available for 293 individuals. Results of T
lymphocyte subset data were available for 286 individuals. Not one
case of active tuberculosis was identified.
A total of 133 individuals or 45.4% of all participants showed true
negative PPD results (PPD negative, mumps andlor tetanus posi
tive). A positive delayed-type hypersensitivity (DTH) response was
observed most frequently with tetanus antigen (38.6%) followed
closely by mumps antigen (36.2%). A positive reaction for both
mumps and tetanus was seen in 25.9%. A total of 148 individuals
showed no reaction to any of the three antigens, demonstrating an
overall 50.5% rate of anergy (Table 2).
Some induration to PPD antigen was observed at 48 to 72 hours
in 15 individuals (5.1%). Ten individuals had induration of5 mm,
meeting the CDC’s criteria for a positive PPD in HIV-infected
individuals.6The five individuals with less than 5 mm induration
underwent repeat skin tests for all three antigens. One of these five
individuals had an initial induration of 4 mm to tuberculin antigen
‘Available for 286/304 pts
Table 2.—Skin Test Results
PPD Anergy Panel N (%)
(one or both>
Positive PPD + + 10(34)
+
- 2(0.7)
True Neg PPD
- + 133(45.4)
Anergic
-
- 148(50.5)
Total 293 (100)
and negative reaction to mumps and tetanus. Repeat tuberculin
testing one month later revealed a 9 mm induration. Mumps and
tetanus remained negative. He was counted as a PPD reactor. The
remaining four individuals who were retested had a <5 mm reaction
or were nonreactive to PPD. Another individual initially showed no
induration to tuberculin antigen at 48 hours but showed a delayed
response to PPD 7 days later. He also was counted as a PPD reactor.
Overall, a positive PPD was found for a total of 12 patients or 4.1%
of the study cohort. None of these individuals reported a history of
BCG vaccination.
Two of the 12 participants with positive PPD had negative
reactions to mumps and tetanus. Seven had positive reactions to
both mumps and tetanus. Two had a positive reaction to tetanus
alone and one had a reaction to mumps alone.
A CD4 count less than 200/mm3was shown to be significantly
associated with an anergic state as compared to a CD4 count greater
than 200/mm3(p <0.05). An inverse relationship of CD4 counts and
anergy was seen (Fig 1).
Of the 12 individuals with positive PPD skin tests, four had CD4
counts of 200/mm3to 299/mm3,three had CD4 of 300 cells/mm3to
399 cells/mm3,one had CD4 of400 cells/mm3to 499 cells/mm.and
three had CD4 of 500 cells/mm3.Only one individual had a CD4
count of less than 200 cells/mm This individual had a CD4 count
of <6 cells/mm3,and was the individual previously described with
a initial 4 mm reaction to tuberculin increasing subsequently to 9
mm on boosting. A significant association was found between
having a CD4 count greater than 200/mm3 and a positive PPD
(p=0.004).
An interesting phenomenon of delayed skin-test positivity was
observed in five patients. The original case involved a 36-year-old
HIV-positive Caucasian man from Maui who was seen in Septem
ber 1994. No induration was noted at the site of his PPD at 48 hours
post-skin-test placement. He did have a 13 mm reaction to tetanus
and a 4 mm reaction to mumps. The patient phoned our research
office with information that he had noted a swelling in the region of
his PPD seven days post placement of the skin tests. The positive
reaction was confirmed and read as a 7 mm induration by the local
HIV care coordinator nurse who is certified in tuberculosis testing.
Unfortunately, no repeat PPD was done and the patient later died of
non-TB-related causes.
All patients subsequent to this case were asked to call if indura
tions developed after the initial 48 to 72 hour reading. No other
delayed reaction to PPD was reported. However, calls were re
ceived from four participants describing delayed reactions to teta
nus and/or mumps from five to ten days post placement of the skin
Table 1.—Demographics
No Patients (% total)
304
40.5/8.0
Fig 1.—Frequency of antigen response according to CD4 T-Lymphocyte
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Patients entered
Age (MeanlStd dev)
Race
African-American
Asian Pacific Islander
caucasian
Latin/Hispanic/Portuguese
Native American
Place of Birth
Mainland
Hawaii
Foreign country
Not given
Risk Behavior
Bisexual
Blood transfusion
Heterosexual sex
Homosexual
Intravenous drug user
Sex with intravenous drug user or bisexual
CD444 count’
50
51-199
200-499
500
<100 100.199 200-299 300-399 400-499 >=500
CD4+ Cell Count
6(2.0)
69 (22.8)
192 (63.4)
27(8.6)
10)3.3)
176 (57.9)
62 (20.4)
16(5.3)
50 16.4
5(1.6)
6(2.0)
19(6.3)
222 (73.0)
15(4.9)
3(1.0)
72 (23.7)
65(21.4)
100(32.9)
49(16.1)
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tests. Two of these individuals underwent repeat skin testing. One
of these individuals was initially anergic but reported a reaction to
tetanus antigen at day eight. He underwent repeat skin tests two
months later and had a positive tetanus reaction of 3 mm. No
reaction was observed to mumps or tuberculin. The second indi
vidual, also initially anergic, reported a positive reaction to mumps
and tetanus at day ten. He was retested four months later and had a
3 mm reaction to tetanus, and negative reactions to mumps and PPD.
Discussion
Hawaii has the highest tuberculosis case rate in the nation with
20.9 cases/I 00,000 individuals.7According to Richard Vogt MD of
the Hawaii Department of Health in September 1995, of the 247
cases of active TB reported to the Hawaii Department of Health in
1994, 224 (9 1%) were AsianlPacific Islanders and only 20 (8%)
were listed as Caucasians. One hundred ninety five patients (79%)
were foreign-born individuals with 127 patients born in the Philip
pines, 17 in Southeast Asia, and 11 from Korea. Tuberculosis in
Hawaii is a problem largely of the immigrant population especially
of Asian/Pacific Islander ancestry and not of the larger local
population.
This study found a PPD reactivity rate of 4.1% among Hawaii’s
HIV-infected population, a rate much lower than expected given the
high overall case rate in the state. Our study cohort consisted of
63.4% Caucasians and 22.8% Asian/Pacific Islanders, an ethnic
composition closely matching the ethnic distribution of AIDS cases
reported to the Hawaii Department of Health (66% Caucasians and
25% Asian/Pacific Islanders),9but very different from the ethnic
distribution of persons with active TB in the state. Thus the HIV
population in Hawaii appears to have a relatively low prevalence of
latent TB and is a population probably distinct from the immigrant
AsianfPacific Islander population responsible for the high preva
lence of tuberculosis in Hawaii.
An overall 50.5% anergy rate was found in our study. A strong
inverse association between the lack of response to DTH testing and
degree of immunosuppression as represented by CD4 counts was
demonstrated. The rate of anergy varied from 22% in individuals
with CD4 counts 500/mm3to 72% in those individuals with a CD4
count of <50/mm3.This high rate of anergy and inverse correlation
with CD4 counts are consistent with other published reports.35’°
Huebner et al studied a total of 479 HI V-infected persons at an HIV
clinic in Florida and a tuberculosis clinic in New Jersey and found
that anergy was four times and 15 times as likely for persons with
CD4 T-lymphocyte counts of 200/mm3to 400/mm3and <200/mm3,
respectively, as for persons with >499 CD4 T-lymphocytes/mm.
Similarly, Graham et al reported an inverse linear trend for PPD
positivity and CD4 lymphocyte count in a cohort of 260 individuals
with history of intravenous drug use in Baltimore.’° Brix et al
reported a 5% anergy rate in HIV-infected individuals with CD4
counts >500/mm3while among individuals with 200 cells/mm3the
anergy rate increased to 38%.
Individuals with a positive reaction to PPD were likely to have a
positive reaction to anergy testing. Ten of the 12 participants with
positive PPD had a positive reaction to DTH antigens. This result is
in contrast to the finding of Markowitz et al who reported no
association between the response to control antigens and tuberculin
reactivity.5Furthermore the ability to mount a positive reaction to
PPD appears heavily dependent on the CD4 count of these individu
als. Eleven of 12 participants in our study (92%) with a positive PPD
had CD4 counts 200. Only one individual with a positive PPD was
detected in the cohort with CD4 counts <200 despite the fact that
close to 50% of the entire cohort had CD4 counts less than 200.
DTH testing is recommended by the 1991 CDC guidelines as an
adjunct to tuberculosis skin testing in the diagnosis of tuberculosis.6
The value of anergy testing, however, has been questioned lately
especially in view of the recent study demonstrating fluctuation of
DTH reaction over time in many HIV-infected individuals. An
anergy study in a cohort of 923 injection drug users at methadone
clinics in Baltimore between 1991 and 1994 demonstrated an initial
anergy rate in HIV-seropositive individuals of 36% and in HIV
seronegative individuals of 14%. Among those who initially were
DTH-positive, anergy developed in 24% of seropositive and 15% of
seronegatives at the next study visit. Among those who initially
were anergic, changes to a positive test took place in 15% of
seropositive and 11% of seronegatives.” Our study supports the
view that DTH testing is imprecise. Neither low CD4 counts nor
anergy to DTH testing is completely predictive of a negative PPD
as demonstrated by our two patients with negative responses to
DTH who nevertheless had a positive reaction to PPD. One of these
individuals had a CD4 count of <6. Our results argue that PPD skin
testing should be considered in all HI V-infected individuals regard
less of their state of anergy or CD4 count.
Recent studies have shown some, although limited, utility in
boosting for those patients with insignificant (<5 mm) PPD and
anergy. Huebneret al6 found seven individuals from a cohort of 130
patients with initially negative PPD tests who responded to boost
ing. Webster et al’2 found 18 patients in a cohort of 709 HI V-infected
patients who demonstrated a booster effect. These boosted re
sponses were seen in 8 (2.1%) anergic patients, 6(4.5%) nonanergic
patients and 4(2.5%) with anergy status unknown. In our study, five
participants with <5 mm reaction to tuberculin antigen underwent
skin testing for the second time. One individual was found to have
a 9mm response to the second PPD. Although numbers were limited
in this study, boosting by repeat PPD may be of value in those with
minimal induration (<5 mm) to tuberculin antigen.
A possible delayed reaction to PPD and anergy testing was
observed in this study, with positive reactions developing after the
standard 48 to 72 hours after placement of the skin tests. In one
instance, 7mm induration developed at the site of the original PPD
seven days after placement. Unfortunately, no biopsies were per
formed to demonstrate a delayed hypersensitivity reaction. Subse
quently, the two other participants self-reported delayed positive
reaction to DTH. On retesting, both showed positive reactions to
DTH antigen. We believe this phenomena should be studied further
and that there may be utility in instructing patients to return if a
delayed response is noted in order to confirm a positive reaction.
In conclusion, our study demonstrates that the HIV population in
Hawaii has a relatively low prevalence of latent TB compared with
the high prevalence of TB in the immigrant Hawaii population.
Despite relatively advanced immunosuppression, PPD skin testing
identified patients for TB prophylaxis. Skin test anergy was in
versely associated with CD4 counts although no level of immuno
suppression could be identified that could reliably predict skin test
anergy. A phenomenon of delayed reaction to skin testing was
observed and merits further study.
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